Dear Editor,
We thank the authors for their thoughtful and constructive comments on our recent report describing a neonate with congenital hyperinsulinism (CHI) harboring a de novo NEUROD1 c.79C>T (p.Leu27Phe) variant. We appreciate the opportunity to clarify and further discuss the points raised.
First, the authors highlighted the allele frequency of the p.Leu27Phe variant in East Asian populations. We agree that population-specific frequency is a crucial parameter in rigorous variant interpretation. Specifically, the NEUROD1 chr2: 181678782G>A variant had an allele frequency of 6.912×10-4 in the Korea4K dataset, which includes approximately 4,000 Korean reference individuals [1]. Therefore, this low frequency in the Korean reference population may support a potential pathogenic classification. However, the phenotypic expressivity and penetrance of NEUROD1 variants—particularly missense substitutions—remain incompletely understood. Pathogenic variants in several transcription factor genes, including HNF1A and HNF4A, exhibit variable penetrance and broad phenotypic spectra [2]. Thus, while the variant frequency warrants caution, it does not categorically exclude a pathogenic role, particularly given its de novo occurrence.
Second, regarding the applicability of a biphasic phenotype, we agree that not all monogenic diabetes genes follow the same model as HNF1A or HNF4A. Our intention was not to generalize this pattern to NEUROD1 but rather to suggest that alterations in transcriptional regulators of β-cell development and insulin secretion could plausibly, under certain conditions, manifest as early-life hyperinsulinism. We recognize that current evidence linking NEUROD1 specifically to CHI is limited, and our report is intended to provide an early clinical observation rather than establish definitive gene-disease causality.
Third, we fully concur that functional studies are essential for establishing pathogenicity. As discussed in our report, the absence of experimental validation represents a key limitation. We are currently conducting in vitro functional analyses to investigate the transcriptional activity, DNA-binding capacity, and downstream regulatory effects of the p.Leu27Phe variant. Such data will be essential to strengthen or refute a causal association.
Fourth, the authors emphasized the importance of robust ClinGen frameworks for establishing gene-disease relationships [3]. We fully support this approach. Our primary objective was not to advocate for the immediate inclusion of NEUROD1 on routine CHI genetic testing panels, but rather to document a novel clinical finding that may inform future evaluation as additional cases and supporting evidence accumulate. Case reports remain a vital tool in the early stages of gene-disease discovery, particularly for rare pediatric endocrine disorders, for which cohort-based evidence accumulates slowly.
In summary, while we recognize that the current evidence is insufficient to confirm a definitive causal link between NEUROD1 and CHI, we believe that the unique combination of a de novo variant, the biological relevance of the gene, and the observed clinical phenotype provides a reasonable basis for reporting this case. We appreciate the authors’ insights and agree that further research—including functional studies and the identification of additional cases—will be essential to clarify the potential role of NEUROD1 in CHI.
We thank the authors for their valuable comments, which have strengthened our interpretation and highlighted important considerations for future work.
Footnotes
Conflicts of interest
No potential conflict of interest relevant to this article was reported.
References
- 1.Jeon S, Choi H, Jeon Y, Choi WH, Choi H, An K, et al. Korea4K: whole genome sequences of 4,157 Koreans with 107 phenotypes derived from extensive health check-ups. Gigascience. 2024;13:giae014. doi: 10.1093/gigascience/giae014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Fajans SS, Bell GI. MODY: history, genetics, pathophysiology, and clinical decision making. Diabetes Care. 2011;34:1878–84. doi: 10.2337/dc11-0035. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Rehm HL, Berg JS, Brooks LD, Bustamante CD, Evans JP, Landrum MJ, et al. ClinGen—the clinical genome resource. N Engl J Med. 2015;372:2235–42. doi: 10.1056/NEJMsr1406261. [DOI] [PMC free article] [PubMed] [Google Scholar]
